NCT04558658

Brief Summary

Detection of Inflammatory Bowel Disease activity by Using new measure : Neutrophil to lymphocyte ratio

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2020

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 16, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 22, 2020

Completed
2 months until next milestone

Study Start

First participant enrolled

December 1, 2020

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2022

Completed
Last Updated

September 22, 2020

Status Verified

September 1, 2020

Enrollment Period

1 year

First QC Date

September 16, 2020

Last Update Submit

September 16, 2020

Conditions

Keywords

neutrophil to lymphocyte ratio

Outcome Measures

Primary Outcomes (1)

  • Neutrophil to lymphocyte ratio in IBD

    Determination of the prognostic value of N/L ratio in patients with IBD as a non invasive measure of disease acitivity

    baseline

Interventions

Complete Blood CountDIAGNOSTIC_TEST

neutrophil to lymphocyte ratio

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients diagnosed IBD by endoscopy, clinical , biochemical correlation and histopathological biopsy

You may qualify if:

  • patients with inflammatory bowel disease, diagnosed by endoscopy, clinical , biochemical correlation and histopathological biopsy

You may not qualify if:

  • patients have :
  • Appendicitis
  • sigmoid diverticular disease
  • Infectious colitis
  • patients known to have cancer colon

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (3)

  • Argeny S, Stift A, Bergmann M, Mittlbock M, Maschke S, Yang Y, Chitsabesan P, Riss S. Prognostic value of preoperative neutrophil-to-lymphocyte ratio in Crohn's disease. Wien Klin Wochenschr. 2018 Jun;130(11-12):398-403. doi: 10.1007/s00508-018-1322-3. Epub 2018 Feb 12.

    PMID: 29435759BACKGROUND
  • Celikbilek M, Dogan S, Ozbakir O, Zararsiz G, Kucuk H, Gursoy S, Yurci A, Guven K, Yucesoy M. Neutrophil-lymphocyte ratio as a predictor of disease severity in ulcerative colitis. J Clin Lab Anal. 2013 Jan;27(1):72-6. doi: 10.1002/jcla.21564. Epub 2013 Jan 4.

    PMID: 23292894BACKGROUND
  • Gao SQ, Huang LD, Dai RJ, Chen DD, Hu WJ, Shan YF. Neutrophil-lymphocyte ratio: a controversial marker in predicting Crohn's disease severity. Int J Clin Exp Pathol. 2015 Nov 1;8(11):14779-85. eCollection 2015.

    PMID: 26823804BACKGROUND

MeSH Terms

Conditions

Inflammatory Bowel Diseases

Interventions

Blood Cell Count

Condition Hierarchy (Ancestors)

GastroenteritisGastrointestinal DiseasesDigestive System DiseasesIntestinal Diseases

Intervention Hierarchy (Ancestors)

Cell CountCytological TechniquesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisHematologic TestsInvestigative TechniquesCell Physiological PhenomenaBlood Physiological PhenomenaCirculatory and Respiratory Physiological Phenomena

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Evaluation of neutrophil-to-lymphocyte ratio in inflammatory bowel disease in assuit university hospitals

Study Record Dates

First Submitted

September 16, 2020

First Posted

September 22, 2020

Study Start

December 1, 2020

Primary Completion

December 1, 2021

Study Completion

January 1, 2022

Last Updated

September 22, 2020

Record last verified: 2020-09